Experts involved in the research suggested that these findings indicate a potential role for FAPI PET/CT imaging in detecting changes in myocardial fibrosis, noting that it could be more sensitive to earlier changes than standard cardiac MRI.

These new findings could help providers differentiate and manage CP associated with different levels of motor impairment, authors of the study indicated.

Researchers believe the new method of assessing treatment responses could pave the way for developing new cancer therapeutics.

Previously, CMS determined that coverage for patients receiving treatment was dependent on their being enrolled in a CMS-approved clinical trial under coverage with evidence development (CED).

FDG-PET scans in these patients allow clinicians to determine whether the tumors are still viable or not, thus playing a significant role in making treatment decisions.

A new study in JACC: Cardiovascular Imaging focuses on a potential new side effect of COVID-19, highlighting the continued importance of monitoring these patients going forward. 

The demand is especially great for asymptomatic individuals of all races and ethnicities.

In the study, patients who had recovered from an COVID infection were injected with a small amount of the 89Zr-labeled radiotracer before undergoing a uExplorer PET/CT scan.